ClinicalTrials.gg
CompletedNCT00440193Updated Feb 27, 2014Results posted

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Enoxaparin followed by VKA in Venous Thrombosis, sponsored by Bayer. Completed at 324 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-27.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,449
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
5th of 36
3,449 · median 120
Started
2007
with 1 other
Phase 3
12 of 36
2 open now
Registered
1st of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 12 in phase 3, and was the 1st registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).

Read the detailed description

Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.

The treatment period was followed by an observational period of 30 days starting the day after the last intake of study medication, regardless of the actual duration of study drug administration. Participants who did not complete the treatment period also entered the observational period. It was also possible that participants did not enter the observational period, e.g. due to withdrawal of consent or termination of study participation. Participants who were transferring from study 11702 DVT (NCT00440193) to the extension study 11899 (NCT00439725) did not enter the observational period.

03

Conditions studied

  • Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed acute symptomatic proximal DVT without symptomatic PE

Exclusion criteria

Exclusion Criteria:

  • Legal lower age limitations (country specific)
  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
  • Other indication for VKA than DVT and/or PE
  • The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,449 participants (actual)

Study arms

  • Experimental
    Rivaroxaban (Xarelto, BAY59-7939)

    Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Active comparator
    Enoxaparin/VKA

    Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)

    Drug: Enoxaparin followed by VKA

Interventions

  • During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.

  • DrugEnoxaparin followed by VKA

    Drug page: Enoxaparin

    Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

Secondary outcomes

  1. Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

  2. Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment

    Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

  3. Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

  4. Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.

    Time frame: 3-, 6- or 12-month study treatment period

  5. Percentage of Participants With All Deaths

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

  6. Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)

    All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.

    Time frame: 3-, 6- or 12-month study treatment period

Other outcomes

  1. Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.

    Time frame: 3-, 6- or 12-month study treatment period

  2. Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries.

    Time frame: Up to 30 days after the last intake of study medication

  3. Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.

    Time frame: Up to 30 days after the last intake of study medication

  4. Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period

    Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.

    Time frame: Up to 30 days after the last intake of study medication

  5. Percentage of Participants With Recurrent DVT During Observational Period

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.

    Time frame: Up to 30 days after the last intake of study medication

  6. Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period

    All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.

    Time frame: Up to 30 days after the last intake of study medication

07

Results

Posted Jan 24, 2013

Participant flow

Participants with confirmed acute proximal symptomatic deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE) were recruited at specialized study sites.

Treatment Period
Participant flow — Treatment Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Started17311718
Participants received treatment17181711
Completed14261367
Not completed305351
Withdrew: Adverse event7467
Withdrew: Death1922
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up1218
Withdrew: Physician decision36
Withdrew: Protocol violation1619
Withdrew: Withdrawal by subject3677
Withdrew: Clinical endpoint reached2825
Withdrew: Study terminated by sponsor10294
Withdrew: Protocol driven decision point22
Withdrew: Switch to commercial drug02
Withdrew: Technical problems11
Withdrew: Participant convenience52
Withdrew: Participant did not receive treatment713
Withdrew: Site closed by investigator02
Observational Period
Participant flow — Observational Period
MilestoneRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Started14251407
Completed13801369
Not completed4538
Withdrew: Adverse event22
Withdrew: Death1520
Withdrew: Lost to follow-up128
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject118
Withdrew: Physician decision10
Withdrew: Clinical endpoint reached10
Withdrew: Participant convenience20

Outcome measures

PrimaryPercentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment2.13.0
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA · Regression, Cox · p = < 0.0001 · Hazard ratio (hr): 0.68 · 95% CI 0.44 to 1.04The standard error of the log hazard ratio was estimated.
SecondaryPercentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment4.05.1
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA · Regression, Cox · p = 0.044 (Nominal p-value) · Hazard ratio (hr): 0.72 · 95% CI 0.53 to 0.99The standard error of the log hazard ratio was estimated.
SecondaryPercentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment2.94.2
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA · Regression, Cox · p = 0.027 (Nominal p-value) · Hazard ratio (hr): 0.67 · 95% CI 0.47 to 0.95The standard error of the log hazard ratio was estimated.
SecondaryPercentage of Participants With Recurrent DVT Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment0.91.6
SecondaryPercentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)8.18.1
Statistical analysis
  • Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA · Regression, Cox · p = 0.77 (Nominal p-value) · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.22The standard error of the log hazard ratio was estimated.
SecondaryPercentage of Participants With All Deaths

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With All Deaths
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
All post-randomization2.43.0
Treatment-emergent (time window: 2 days)1.01.1
Treatment-emergent (time window: 7 days)1.21.5
SecondaryPercentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)

All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)0.70.8
Other pre-specifiedPercentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Death (PE)0.060
Death (PE cannot be excluded)0.20.3
Symptomatic PE and DVT0.060
Symptomatic recurrent PE only1.21.0
Symptomatic recurrent DVT only0.81.6
Death (bleeding)0.060.3
Death (cardiovascular)0.10.2
Death (other)1.82.0
Major bleeding0.91.3
Other pre-specifiedPercentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period0.80.5
Other pre-specifiedPercentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period2.21.8
Other pre-specifiedPercentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period

Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period1.11.1
Other pre-specifiedPercentage of Participants With Recurrent DVT During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With Recurrent DVT During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With Recurrent DVT During Observational Period0.60.3
Other pre-specifiedPercentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period

All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Death (PE)00
Death (PE cannot be excluded)0.070.07
Symptomatic PE and DVT00
Symptomatic recurrent PE only0.30.1
Symptomatic recurrent DVT only0.60.3
Death (bleeding)0.070.1
Death (cardiovascular)0.070.3
Death (other)1.30.8
Major bleeding0.20.6
Post-hocPercentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries

Time frame:
3-, 6- or 12-month study treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment3.64.7
Post-hocPercentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period

Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.

Time frame:
Up to 30 days after the last intake of study medication
Reported as:
Number · Percentage of participants
Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period
Percentage of participantsRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period1.21.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban (Xarelto, BAY59-7939)—222/1,718 (12.9%)241/1,718 (14%)
Enoxaparin/VKA—252/1,711 (14.7%)212/1,711 (12.4%)
Most frequent serious events
Showing 10 of 404
Most frequent serious events
EventRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
AnaemiaBlood and lymphatic system disorders11/17188/1711
PneumoniaInfections and infestations5/171810/1711
HaematuriaRenal and urinary disorders4/17188/1711
SepsisInfections and infestations2/17187/1711
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/17187/1711
Ischaemic strokeNervous system disorders4/17187/1711
Alanine aminotransferase increasedInvestigations2/17186/1711
International normalised ratio increasedInvestigations0/17185/1711
Hepatic enzyme increasedInvestigations1/17185/1711
DyspnoeaRespiratory, thoracic and mediastinal disorders2/17185/1711
Most frequent other events
Most frequent other events
EventRivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKA
NasopharyngitisInfections and infestations100/171891/1711
HeadacheNervous system disorders91/171870/1711
EpistaxisRespiratory, thoracic and mediastinal disorders90/171874/1711

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKATotal
Mean55.8 ± 16.456.4 ± 16.356.1 ± 16.4
Age, Customized
Age, Customized(participants)Rivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKATotal
18 - < 40 years314279593
40 - < 60 years6426621304
60 - < 75 years5305191049
≥ 75 years245258503
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban (Xarelto, BAY59-7939)Enoxaparin/VKATotal
Female7387511489
Male9939671960
08

Study locations

324 sites
  • Little Rock, Arkansas 72205, United States
  • Redlands, California 92373, United States
  • Bay Pines, Florida 33744, United States
  • Miami, Florida 33136-1096, United States
  • Miami, Florida 33136, United States
  • Idaho Falls, Idaho 83404, United States
  • Covington, Louisiana 70433, United States
  • Baltimore, Maryland 21215, United States
  • Boston, Massachusetts 02215, United States
  • Albuquerque, New Mexico 87108-4763, United States
  • Chapel Hill, North Carolina 27599-7035, United States
  • Greensboro, North Carolina 27401, United States
  • Greensboro, North Carolina 27403, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Corsicana, Texas 75110, United States
  • San Antonio, Texas 78229, United States
  • Murray, Utah 84157, United States
  • Salt Lake City, Utah 84132, United States
  • Fredericksburg, Virginia 22401, United States
  • Spokane, Washington 99204, United States
  • Tacoma, Washington 98405, United States
  • Garran, Australian Capital Territory 2605, Australia
  • Darlinghurst, New South Wales 2010, Australia
  • Gosford, New South Wales 2250, Australia
  • Kogarah, New South Wales 2217, Australia
  • Lismore, New South Wales 2480, Australia
  • St Leonards, New South Wales 2065, Australia
  • Sydney, New South Wales 2031, Australia
  • Sydney, New South Wales 2139, Australia
  • Sydney, New South Wales 2229, Australia
  • Brisbane, Queensland 4029, Australia
  • Redcliffe, Queensland 4020, Australia
  • Southport, Queensland 4215, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Adelaide, South Australia 5042, Australia
  • Woodville South, South Australia 5011, Australia
  • Box Hill, Victoria 3128, Australia
  • Clayton, Victoria 3168, Australia
  • Geelong, Victoria 3220, Australia
  • Melbourne, Victoria 3135, Australia
  • Melbourne, Victoria 3181, Australia
  • Fremantle, Western Australia 6160, Australia
  • Perth, Western Australia 6000, Australia
  • Graz, Steiermark 8036, Austria
  • Feldkirch, Vorarlberg 6807, Austria
  • Innsbruck, 6020, Austria
  • Salzburg, 5020, Austria
  • Wien, 1090, Austria
  • Wien, 1140, Austria
  • Bruxelles - Brussel, 1070, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Duffel, 2570, Belgium
  • Genk, 3600, Belgium
  • Gent, 9000, Belgium
  • Hasselt, 3500, Belgium
  • Leuven, 3000, Belgium
  • Liege, 4000, Belgium
  • Lier, 2500, Belgium
  • Namur, 5000, Belgium
  • Yvoir, 5530, Belgium
  • Zottegem, 9620, Belgium
  • Uberaba, Minas Gerais 38010 380, Brazil
  • Curitiba, Parana 80050-350, Brazil
  • Londrina, Parana 86038440, Brazil
  • Botucatu, Sao Paulo 18618 000, Brazil
  • Sorocaba, Sao Paulo 18031-000, Brazil
  • São Paulo, Sao Paulo 04039-004, Brazil
  • Sao Paulo, SP 01509-900, Brazil
  • Sao Paulo, SP 04023-061, Brazil
  • São Paulo, SP 01323-001, Brazil
  • Rio de Janeiro, Brazil
  • Winnipeg, Manitoba R2H 2A6, Canada
  • London, Ontario N6A 4G5, Canada
  • Ottawa, Ontario K1Y 4E9, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M6R 1B5, Canada
  • Guangzhou, Guangdong 510000, China
  • Guangzhou, Guangdong 510120, China
  • Harbin, Heilongjiang 150086, China
  • Wuhan, Hubei 430022, China
  • Suzhou, Jiangsu 215004, China
  • Shenyang, Liaoning 110016, China
  • Hangzhou, Zhejiang 310016, China
  • Beijing, 100020, China
  • Beijing, 100029, China
  • Beijing, 100037, China
  • Beijing, 100038, China
  • Beijing, 100044, China
  • Beijing, 100730, China
  • Beijing, 100853, China
  • Shanghai, 200001, China
  • Shanghai, 200032, China
  • Shanghai, 200433, China
  • Karlovy Vary, 360 00, Czech Republic
  • Kladno, 27259, Czech Republic
  • Ostrava-Poruba, 708 52, Czech Republic
  • Ostrava, 728 80, Czech Republic
  • Prague 5, 150 00, Czech Republic

Showing the first 100 of 324 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. PubMed 21128814 ↗
  • Cohen AT, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. PubMed 22371186 ↗
  • Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J. 2013 Jul 6;11(1):13. doi: 10.1186/1477-9560-11-13. PubMed 23829521 ↗
  • Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21. PubMed 24053656 ↗
  • Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, Meng IL, Prins MH, Pap AF, Muller K, Lensing AW; Chinese EINSTEIN Investigators. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J. 2013 Dec 16;11(1):25. doi: 10.1186/1477-9560-11-25. PubMed 24341332 ↗
  • Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost. 2013 Oct;110(4):732-41. doi: 10.1160/TH13-03-0243. Epub 2013 Jul 11. PubMed 23846019 ↗
  • van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22. PubMed 24432872 ↗
  • Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012 Sep 26;10:120. doi: 10.1186/1477-7525-10-120. PubMed 23013426 ↗
  • Yang L, Wu J. Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. BMJ Open. 2020 Jul 30;10(7):e038433. doi: 10.1136/bmjopen-2020-038433. PubMed 32737096 ↗
  • Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15. PubMed 30121419 ↗
  • Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost. 2016 Sep 27;116(4):739-46. doi: 10.1160/TH16-02-0087. Epub 2016 Aug 18. PubMed 27535349 ↗
  • Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J. 2014 Nov 26;12:26. doi: 10.1186/1477-9560-12-26. eCollection 2014. PubMed 25698905 ↗
  • Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap AF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28. PubMed 27030066 ↗
  • Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, Beyer-Westendorf J, Prandoni P. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014. PubMed 25750589 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years 9 months after primary completion. A results delay was requested in Dec 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2007
First posted
Feb 26, 2007
Start
Mar 2007
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results delay requested
Dec 21, 2011
Results first posted
Jan 24, 2013
Last update
Feb 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00440193
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 26, 2007
Start date
Mar 2007
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Jan 24, 2013
Last update
Feb 27, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion